Categories Earnings, Health Care

Bausch Health’s stock gains on improved outlook

Bausch Health Companies Inc. (NYSE: BHC) missed revenue expectations for the first quarter of 2019 and did not provide a number for adjusted EPS. The company raised its full-year 2019 guidance, allowing shares to gain 2.6% in premarket hours on Monday.

Total revenues of $2.01 billion were up 1% compared to the same period last year. Organic sales growth was 5%.

Bausch Health reports first quarter 2019 earnings

GAAP net loss was $52 million, or $0.15 per share, compared to $2.5 billion, or $7.36 per share, in the year-ago quarter. Adjusted net income increased 15% to $358 million.

Revenues in the Bausch + Lomb/International segment increased 1% year-over-year to $1.11 billion while revenues in the Salix segment grew 5% to $445 million.

In the Ortho Dermatologics segment, revenues fell 1% to $138 million, due to lower volumes primarily driven by the loss of exclusivity of ELIDEL, ZOVIRAX and SOLODYN. In Diversified Products, revenues dropped 5% to $315 million, mainly due to a loss of exclusivity for a basket of products.

Also see: Bausch Health Q1 2019 Earnings Conference Call Transcript

For the full year of 2019, the company now expects revenues to be $8.35 billion to $8.55 billion compared to the prior outlook of $8.30 billion to $8.50 billion.

Bausch completed the acquisition of certain assets of Synergy Pharmaceuticals Inc., including TRULANCE and dolcanatide for a cash purchase price, including restructuring, of approx. $190 million and the assumption of certain liabilities.

The FDA approved DUOBRII lotion for the topical treatment of plaque psoriasis in adults. DUOBRII is expected to be launched in June 2019.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Key highlights from Autodesk (ADSK) Q4 2021 earnings results

Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per

Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%

Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus

Virgin Galactic stock tanks on delayed test flight

Virgin Galactic (NYSE: SPCE) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The space tourism company reported zero revenue in the fourth quarter, compared to $529,000

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top